JP2008505087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505087A5 JP2008505087A5 JP2007519344A JP2007519344A JP2008505087A5 JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5 JP 2007519344 A JP2007519344 A JP 2007519344A JP 2007519344 A JP2007519344 A JP 2007519344A JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5
- Authority
- JP
- Japan
- Prior art keywords
- glucagon
- insulin
- amount
- milliunits
- units
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 52
- 102000051325 Glucagon Human genes 0.000 claims 43
- 108060003199 Glucagon Proteins 0.000 claims 43
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 43
- 229960004666 glucagon Drugs 0.000 claims 43
- 102000004877 Insulin Human genes 0.000 claims 26
- 108090001061 Insulin Proteins 0.000 claims 26
- 229940125396 insulin Drugs 0.000 claims 26
- 230000002218 hypoglycaemic effect Effects 0.000 claims 9
- 208000013016 Hypoglycemia Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 239000012731 long-acting form Substances 0.000 claims 4
- 102000007327 Protamines Human genes 0.000 claims 3
- 108010007568 Protamines Proteins 0.000 claims 3
- 229940048914 protamine Drugs 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000003443 Unconsciousness Diseases 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58444904P | 2004-06-29 | 2004-06-29 | |
| PCT/US2005/022812 WO2006004696A2 (en) | 2004-06-29 | 2005-06-27 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505087A JP2008505087A (ja) | 2008-02-21 |
| JP2008505087A5 true JP2008505087A5 (enExample) | 2008-07-31 |
Family
ID=35783298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007519344A Pending JP2008505087A (ja) | 2004-06-29 | 2005-06-27 | インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1778266A4 (enExample) |
| JP (1) | JP2008505087A (enExample) |
| KR (1) | KR20070029276A (enExample) |
| CN (1) | CN101001638A (enExample) |
| AU (1) | AU2005260025A1 (enExample) |
| CA (1) | CA2571030A1 (enExample) |
| IL (1) | IL180361A0 (enExample) |
| MX (1) | MXPA06014970A (enExample) |
| NO (1) | NO20070174L (enExample) |
| WO (1) | WO2006004696A2 (enExample) |
| ZA (1) | ZA200700708B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2816114C (en) | 2010-11-03 | 2019-02-12 | Jan Jezek | Novel composition comprising glucagon |
| CN107949374B (zh) * | 2015-09-04 | 2022-04-08 | 莱迪杜德制药公司 | 稳定的胰高血糖素溶液 |
| GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
| CN110446496A (zh) * | 2017-02-03 | 2019-11-12 | 范德比尔特大学 | 用于治疗糖尿病的系统、组合物和方法 |
| BR112020000447A2 (pt) * | 2017-07-14 | 2020-07-21 | Xeris Pharmaceuticals, Inc. | métodos de tratamento de hiperinsulinismo congênito |
| WO2019108640A1 (en) * | 2017-11-28 | 2019-06-06 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods and kits for evaluating metabolism |
| WO2021263197A1 (en) * | 2020-06-26 | 2021-12-30 | Xeris Pharmaceuticals, Inc. | Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same |
| GB202109087D0 (en) * | 2021-06-24 | 2021-08-11 | Norwegian Univ Sci & Tech Ntnu | Therapeutic methods and devices |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3897551A (en) * | 1971-04-05 | 1975-07-29 | Lilly Co Eli | Iodoglucagons and process for prolonging the biological activity of glucagon |
| US5321008A (en) * | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
| WO2004046106A1 (en) * | 2002-11-18 | 2004-06-03 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
| CN1732012A (zh) * | 2002-12-27 | 2006-02-08 | 迪奥贝克斯公司 | 用于预防和控制胰岛素诱发的低血糖的组合物和方法 |
-
2005
- 2005-06-27 JP JP2007519344A patent/JP2008505087A/ja active Pending
- 2005-06-27 CA CA002571030A patent/CA2571030A1/en not_active Abandoned
- 2005-06-27 WO PCT/US2005/022812 patent/WO2006004696A2/en not_active Ceased
- 2005-06-27 MX MXPA06014970A patent/MXPA06014970A/es not_active Application Discontinuation
- 2005-06-27 EP EP05787795A patent/EP1778266A4/en not_active Withdrawn
- 2005-06-27 KR KR1020077002164A patent/KR20070029276A/ko not_active Withdrawn
- 2005-06-27 ZA ZA200700708A patent/ZA200700708B/xx unknown
- 2005-06-27 AU AU2005260025A patent/AU2005260025A1/en not_active Abandoned
- 2005-06-27 CN CNA2005800270476A patent/CN101001638A/zh active Pending
-
2006
- 2006-12-26 IL IL180361A patent/IL180361A0/en unknown
-
2007
- 2007-01-10 NO NO20070174A patent/NO20070174L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023237119B2 (en) | Buffered formulations of exendin (9-39) | |
| Whitehead et al. | Oral delivery of macromolecules using intestinal patches: applications for insulin delivery | |
| AU2015204491B2 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| JP2020033360A5 (enExample) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2014524480A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| JP2021503468A5 (enExample) | ||
| JP2005501110A5 (enExample) | ||
| KR102231074B1 (ko) | 인슐린 글라진/릭시세나티드 고정비 제형 | |
| JP2005520778A5 (enExample) | ||
| JP2013522194A5 (enExample) | ||
| CN103167878A (zh) | 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病 | |
| ES2922551T3 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| ME01546B (me) | Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2 | |
| CA2971440C (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| JP2020500864A5 (enExample) | ||
| JP2008505087A5 (enExample) | ||
| JP2010516671A (ja) | 糖尿病の治療のためのエクセナチド及びダラルギンに基づく医薬、その使用及び治療方法 | |
| Becker et al. | Dose-response relationship of insulin glulisine in subjects with type 1 diabetes | |
| JP2008517991A5 (enExample) | ||
| Bush | Intensive diabetes therapy and body weight: focus on insulin detemir | |
| WO2019050712A1 (en) | SUBLINGUAL EPINEPHRINE TABLETS | |
| US20220265776A1 (en) | Combination | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis |